Alligator Bioscience: BioStock: Alligator's CEO: "We are on track to secure a partnership"
Alligator Bioscience is undertaking a restructuring and planning a rights issue of approximately SEK 280 million. This move aims to concentrate efforts on its lead drug candidate, mitazalimab, with the goal of securing a partnership and advancing it to a phase III trial. BioStock spoke with CEO Søren Bregenholt to learn more.
Read the interview with Alligator Bioscience at biostock.se:
https://www.biostock.se/en/2024/12/alligators-ceo-we-are-on-track-to-secure-a-partnership/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/